Gastroenterology Practice Questions

Q: Which of the following statements about peptic ulcer disease is true?

The incidence of complications has remained unchanged.. ### Explanation **Correct Option: B. The incidence of complications has remained unchanged.** While the overall incidence of Peptic Ulcer Disease (PUD) has significantly declined due to effective *H. pylori* eradication and the widespread use of Proton Pump Inhibitors (PPIs), the incidence of **complications** (such as perforation and hemorrhage) has remained relatively stable. This is primarily attributed to the increasing use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and low-dose aspirin among the aging population, which offsets the gains made by treating *H. pylori* [1]. **Analysis of Incorrect Options:** * **Option A:** *H. pylori* eradication **decreases** the likelihood of complications. It is the most effective strategy to prevent ulcer recurrence and subsequent bleeding or perforation [1]. * **Option C:** In developing countries like India, the reinfection rate of *H. pylori* is **high** (often >2% per year) due to overcrowding, poor sanitation, and contaminated water sources, unlike the low rates (<1%) seen in developed nations. * **Option D:** *H. pylori* eradication **dramatically alters** the recurrence ratio. Without eradication, ulcer recurrence rates are 60–90%; after successful eradication, this drops to <10% [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Most common complication of PUD:** Upper GI Bleed (Hematemesis/Melena) [1]. * **Most common site of perforation:** Anterior wall of the duodenum [1]. * **H. pylori Association:** Strongly linked to Duodenal Ulcers (90-95%) more than Gastric Ulcers (70-80%) [1]. * **Investigation of Choice:** Upper GI Endoscopy (UGIE). * **Gold Standard for H. pylori diagnosis:** Endoscopic biopsy followed by Histopathology (though Urease Breath Test is the best non-invasive test for confirming eradication) [1].

Q: A 30-year-old patient has persistent antibodies to HCV for 6 months with normal AST/ALT levels and no symptoms or stigmata of liver disease. What is the most appropriate next step in management?

Determine HCV RNA levels. ### Explanation The presence of **HCV antibodies (Anti-HCV)** indicates that the patient has been exposed to the Hepatitis C virus at some point. However, it does not distinguish between an active (chronic) infection and a resolved past infection [1]. **1. Why Option D is Correct:** In Hepatitis C, approximately 15–25% of patients clear the virus spontaneously but remain antibody-positive for life [1]. Furthermore, chronic HCV infection is often "clinically silent," where patients may have **persistently normal ALT/AST levels** despite ongoing viral replication and progressive liver fibrosis [1]. Therefore, the presence of antibodies must always be followed by a **qualitative or quantitative HCV RNA test (PCR)** to confirm active viremia [1]. If HCV RNA is detected, the patient has chronic hepatitis C and requires treatment, regardless of enzyme levels. **2. Why Other Options are Incorrect:** * **Option A & B:** Reassurance or simply repeating antibody titers is inappropriate because the patient may have active, transmissible chronic infection that can lead to cirrhosis or HCC if left untreated. Antibody titers do not correlate with disease activity. * **Option C:** Normal liver enzymes are not a reliable indicator of viral clearance. Up to 30% of patients with chronic HCV have normal ALT levels. Relying on enzymes alone would miss a significant number of chronic cases. **Clinical Pearls for NEET-PG:** * **Screening Test:** Anti-HCV (ELISA). * **Confirmatory/Gold Standard for Active Infection:** HCV RNA by PCR [1]. * **Treatment Goal:** Sustained Virologic Response (SVR), defined as undetectable HCV RNA 12–24 weeks after completing antiviral therapy. * **High-Yield Fact:** Unlike Hepatitis B, Hepatitis C does not integrate into the host genome; therefore, it is potentially curable with Direct-Acting Antivirals (DAAs).

Q: All of the following are true for patients with ulcerative colitis associated with primary sclerosing cholangitis (PSC), EXCEPT:

PSC reverses after a total colectomy.. The correct answer is **D**. The underlying medical concept is that **Primary Sclerosing Cholangitis (PSC)** follows a clinical course independent of the underlying **Ulcerative Colitis (UC)** [2]. While approximately 70-80% of PSC patients have UC [3], performing a total colectomy (which is curative for the intestinal symptoms of UC) does not halt, reverse, or prevent the progression of PSC or the risk of associated biliary malignancies. **Analysis of Options:** * **Option A (Biliary Cirrhosis):** True. PSC is a chronic cholestatic disease characterized by progressive inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. This leads to "beading" on imaging and eventually results in secondary biliary cirrhosis and liver failure. * **Option B (Raised Alkaline Phosphatase):** True. A cholestatic pattern of liver enzymes is the hallmark of PSC. An elevated serum alkaline phosphatase (ALP) is often the first biochemical abnormality detected, even in asymptomatic patients [1]. * **Option C (Hilar Cholangiocarcinoma):** True. Patients with PSC have a significantly increased lifetime risk (up to 10-15%) of developing cholangiocarcinoma, most commonly at the biliary confluence (Klatskin tumor/hilar type). **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** MRCP (shows "string of beads" appearance). Liver biopsy shows pathognomonic **"onion-skin" fibrosis**. * **Antibody:** p-ANCA is positive in 60-80% of cases [1], [3]. * **Cancer Risks:** PSC increases the risk of both **Cholangiocarcinoma** and **Colorectal Cancer** (more so than UC alone). * **Treatment:** Liver transplantation is the only definitive treatment for end-stage PSC; medical therapies like Ursodeoxycholic acid (UDCA) improve biochemistry but not survival.

Q: A 41-year-old male patient presented with recurrent episodes of bloody diarrhea for 5 years. Despite regular treatment with adequate doses of sulfasalazine, he has had several exacerbations of his disease and required several weeks of steroids for the control of flares. What should be the next line of treatment for him?

Azathioprine. ### Explanation The patient presents with chronic, relapsing **Ulcerative Colitis (UC)** that is **steroid-dependent**. He has failed maintenance therapy with 5-ASA (Sulfasalazine) and requires repeated courses of corticosteroids to control flares. [1] **1. Why Azathioprine is Correct:** In inflammatory bowel disease (IBD), when a patient cannot taper off steroids without a relapse or requires frequent steroid pulses, they are classified as "steroid-dependent." The standard next step in management is the introduction of **Thiopurines (Azathioprine or 6-Mercaptopurine)**. These are "steroid-sparing agents" used for the maintenance of remission in UC. [1] They take 3–6 months to reach peak efficacy, making them unsuitable for acute flares but ideal for long-term control in this scenario. **2. Why Other Options are Incorrect:** * **A. Methotrexate:** While used as a second-line immunomodulator in **Crohn’s Disease**, its efficacy in Ulcerative Colitis is not well-established and is generally not the first-choice steroid-sparing agent for UC. * **C. Cyclosporine:** This is a potent immunosuppressant used for **acute severe ulcerative colitis** (refractory to IV steroids) as "rescue therapy" to avoid emergency colectomy. It is not used for routine maintenance in a stable but steroid-dependent patient. * **D. Cyclophosphamide:** This drug has no established role in the standard management of Ulcerative Colitis due to its significant toxicity profile. **Clinical Pearls for NEET-PG:** * **Step-up Therapy:** 5-ASA → Steroids (for induction) → Thiopurines (for maintenance) → Biologics (Infliximab/Adalimumab) → Surgery. [1] * **Monitoring:** Before starting Azathioprine, check **TPMT (Thiopurine Methyltransferase)** activity to predict the risk of severe bone marrow suppression. * **Side Effects:** Monitor for pancreatitis, leucopenia, and increased risk of non-melanoma skin cancer/lymphoma.

Q: Which of the following is NOT a precipitating factor of hepatic encephalopathy in a patient with chronic liver disease?

Hyperkalemia. Hepatic Encephalopathy (HE) is a reversible neuropsychiatric syndrome caused by the accumulation of neurotoxins (primarily ammonia) in the brain due to liver failure or portosystemic shunting [1]. **Why Hyperkalemia is the Correct Answer:** **Hypokalemia**, not hyperkalemia, is a classic precipitant of HE. When potassium levels are low, the body attempts to conserve $K^+$ in the renal tubules by exchanging it for $H^+$ ions. This intracellular acidosis in renal cells stimulates the enzyme glutaminase, leading to increased **renal ammoniagenesis** (production of $NH_3$). Furthermore, hypokalemia-induced alkalosis shifts the equilibrium from ammonium ($NH_4^+$) to ammonia ($NH_3$), which easily crosses the blood-brain barrier. **Analysis of Incorrect Options:** * **TIPS:** This procedure creates a low-resistance tract between the portal and systemic circulation [1]. By bypassing the liver's detoxification process, neurotoxins reach the systemic circulation directly, making HE a common post-procedural complication. * **High Dietary Protein:** Protein breakdown by colonic bacteria produces ammonia [1]. A sudden large protein load (or GI bleed, which is essentially a protein load) increases ammonia production beyond the liver's capacity to clear it. * **Infection:** Sepsis and spontaneous bacterial peritonitis (SBP) increase tissue catabolism and impair renal function, both of which elevate blood ammonia levels and increase the permeability of the blood-brain barrier. **High-Yield Clinical Pearls for NEET-PG:** * **Most common precipitant:** Azotemia (often due to over-diuresis) and Infections. * **Electrolyte disturbances:** Hypokalemia, Hyponatremia, and Metabolic Alkalosis all precipitate HE. * **Drug of choice:** **Lactulose** (converts $NH_3$ to non-absorbable $NH_4^+$ and acts as an osmotic laxative). * **Second-line/Add-on:** **Rifaximin** (non-absorbable antibiotic that reduces ammonia-producing gut flora).

Q: Oral ulceration resembling aphthae are encountered in which of the following conditions?

Gluten enteropathy. **Explanation:** **1. Why Gluten Enteropathy is Correct:** Gluten enteropathy (Celiac Disease) is a common systemic cause of recurrent aphthous-like ulcers. These oral lesions often precede gastrointestinal symptoms. The underlying mechanism is two-fold: first, the **malabsorption** of essential nutrients (specifically Iron, Vitamin B12, and Folate) due to villous atrophy in the small intestine; and second, an **immunological cross-reactivity** where the oral mucosa becomes a target of the inflammatory process. In many patients, a gluten-free diet leads to the complete resolution of these ulcers. **2. Why the Other Options are Incorrect:** * **Chronic Smokers:** Interestingly, smoking is considered "protective" against aphthous ulcers. Nicotine stimulates the production of adrenal steroids and increases keratinization of the oral mucosa, making it less susceptible to ulceration. Ulcers often flare up *after* smoking cessation. * **Excess of B-complex vitamins:** It is the **deficiency** (specifically B1, B2, B6, and B12), not the excess, that causes oral manifestations like glossitis, cheilosis, and aphthous ulcers. * **Anti-malarial medication:** While some drugs (like NSAIDs or Nicorandil) cause oral ulcers, anti-malarials (e.g., Hydroxychloroquine) are actually sometimes used off-label to *treat* severe recurrent aphthous stomatitis due to their immunomodulatory effects. **Clinical Pearls for NEET-PG:** * **RAS (Recurrent Aphthous Stomatitis)** is also strongly associated with **Behçet’s Disease** (pustular/genital sores) and **IBD** (Crohn’s > UC). * **Dermatitis Herpetiformis** is the pathognomonic skin manifestation of Celiac disease. * **Screening Gold Standard:** IgA Anti-tissue Transglutaminase (tTG) antibodies.

Q: A 40-year-old male presents with hematemesis. On examination, his BP was 90/60 mmHg and heart rate was 120/min. Splenomegaly was also present. What is the most probable cause of his bleeding?

Portal hypertension. ### Explanation The clinical presentation of **hematemesis** associated with **splenomegaly** and signs of **hemodynamic instability** (hypotension and tachycardia) strongly points toward **Portal Hypertension**, most commonly due to liver cirrhosis or non-cirrhotic portal fibrosis [1]. **1. Why Portal Hypertension is correct:** In portal hypertension, the increased pressure in the portal venous system leads to the development of portosystemic collaterals [2]. The most clinically significant collaterals are **esophageal and gastric varices**, which are prone to rupture, causing massive, life-threatening hematemesis [2]. The presence of **splenomegaly** is a hallmark sign of portal hypertension, resulting from chronic passive congestion of the spleen (congestive splenomegaly) [1]. **2. Why the other options are incorrect:** * **Gastric and Duodenal Ulcers (Options B & C):** While Peptic Ulcer Disease (PUD) is the most common cause of upper GI bleeding overall, it does **not** cause splenomegaly [1]. The presence of an enlarged spleen specifically shifts the differential toward portal venous pathology. * **Drug-induced GI injury (Option D):** NSAIDs or steroids can cause erosive gastritis or ulcers leading to hematemesis, but like PUD, they do not account for the finding of splenomegaly [1]. **Clinical Pearls for NEET-PG:** * **Most common cause of Portal HTN in India:** Liver Cirrhosis (Alcoholic/Viral). * **Most common cause of massive hematemesis in children with splenomegaly:** Extrahepatic Portal Venous Obstruction (EHPVO). * **Management Priority:** In a patient with BP 90/60 and HR 120, the immediate priority is **hemodynamic stabilization** (IV fluids/blood) before diagnostic endoscopy [1]. * **Drug of choice for active variceal bleed:** Terlipressin or Octreotide. * **Definitive treatment for acute variceal bleed:** Endoscopic Variceal Ligation (EVL).

Question 1

Which of the following statements about peptic ulcer disease is true?

Accepted Answer

The incidence of complications has remained unchanged.

Answer

Helicobacter pylori eradication increases the likelihood of occurrence of complications.

Answer

The incidence of Helicobacter pylori reinfection in India is very low.

Answer

Helicobacter pylori eradication does not alter the recurrence ratio.

Question 2

A 30-year-old patient has persistent antibodies to HCV for 6 months with normal AST/ALT levels and no symptoms or stigmata of liver disease. What is the most appropriate next step in management?

Accepted Answer

Determine HCV RNA levels

Answer

Reassure the patient

Answer

Repeat antibody titre every three years

Answer

Repeat liver enzymes every year

Question 3

All of the following are true for patients with ulcerative colitis associated with primary sclerosing cholangitis (PSC), EXCEPT:

Accepted Answer

PSC reverses after a total colectomy.

Answer

They may develop biliary cirrhosis.

Answer

May have a raised alkaline phosphatase.

Answer

Increased risk of hilar cholangiocarcinoma.

Question 4

A patient with a known history of pancreatitis presents on Day 4 with breathlessness and basal crepitations. What is the most likely diagnosis?

Accepted Answer

Acute respiratory distress syndrome (ARDS)

Answer

Atelectasis

Answer

Pleural effusions

Answer

Aspiration pneumonia

Question 5

A 41-year-old male patient presented with recurrent episodes of bloody diarrhea for 5 years. Despite regular treatment with adequate doses of sulfasalazine, he has had several exacerbations of his disease and required several weeks of steroids for the control of flares. What should be the next line of treatment for him?

Accepted Answer

Azathioprine

Answer

Methotrexate

Answer

Cyclosporine

Answer

Cyclophosphamide

Question 6

Which of the following is NOT a precipitating factor of hepatic encephalopathy in a patient with chronic liver disease?

Accepted Answer

Hyperkalemia

Answer

TIPS (Transjugular Intrahepatic Portosystemic Shunt)

Answer

High dietary protein load

Answer

Infection

Question 7

Oral ulceration resembling aphthae are encountered in which of the following conditions?

Accepted Answer

Gluten enteropathy

Answer

Chronic smokers

Answer

Excess of B-complex vitamins

Answer

Anti-malarial medication

Question 8

A 40-year-old male presents with hematemesis. On examination, his BP was 90/60 mmHg and heart rate was 120/min. Splenomegaly was also present. What is the most probable cause of his bleeding?

Accepted Answer

Portal hypertension

Answer

Gastric ulcer

Answer

Duodenal ulcer

Answer

Drug-induced GI injury

Question 9

A 56-year-old man presents with jaundice and mild fatigue over the past 2 months. He is not on any medications and has no significant past medical history. Physical examination reveals scleral icterus. Laboratory findings include: SGOT: 0.58 microkat/L, SGPT: 0.58 microkat/L, Total bilirubin: 91.7 micromol/L, Direct bilirubin: 85.5 micromol/L, and Alkaline phosphatase: 12 microkat/L. What is the next appropriate diagnostic step?

Accepted Answer

Ultrasound

Answer

Liver biopsy

Answer

Review of peripheral blood smear

Answer

Endoscopic retrograde cholangiopancreatography (ERCP)

Question 10

A patient with chronic liver disease presents with ascites and has no history of bleeding varices. The patient develops hematemesis and melena. What is the next step in management?

Accepted Answer

Fresh frozen plasma transfusion

Answer

Injectable vitamin K

Answer

Injectable Tranexamic acid

Answer

Platelet transfusion

Gastroenterology — MCQs

Gastroenterology — MCQs

On this page

Practice by Chapter

Want unlimited practice?